Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Payables (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Payables data on record, last reported at $786000.0 in Q3 2025.

  • For Q3 2025, Payables fell 43.74% year-over-year to $786000.0; the TTM value through Sep 2025 reached $786000.0, down 43.74%, while the annual FY2024 figure was $1.8 million, 185.2% up from the prior year.
  • Payables reached $786000.0 in Q3 2025 per CTNM's latest filing, down from $2.0 million in the prior quarter.
  • Across five years, Payables topped out at $3.6 million in Q1 2025 and bottomed at $570000.0 in Q1 2024.
  • Average Payables over 3 years is $1.4 million, with a median of $1.1 million recorded in 2024.
  • The widest YoY moves for Payables: up 539.47% in 2025, down 43.74% in 2025.
  • A 3-year view of Payables shows it stood at $635000.0 in 2023, then skyrocketed by 185.2% to $1.8 million in 2024, then plummeted by 56.6% to $786000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $786000.0 in Q3 2025, $2.0 million in Q2 2025, and $3.6 million in Q1 2025.